Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers-Reference-Cited by-同舟云学术

Strategies for mitigating adverse events related to selective RET inhibitors in patients with RET-altered cancers

Published:2023-12 Issue:12 Volume:4 Page:101332
ISSN:2666-3791
Container-title:Cell Reports Medicine
language:en
Short-container-title:Cell Reports Medicine

Author:

Nardo Mirella,Gouda Mohamed A.^ORCID,Nelson Blessie E.,Barreto Carmelia M.N.,Slade J. Hoyt,Poullard Anna,Zafereo Mark,Hu Mimi I.,Cabanillas Maria E.,Subbiah Vivek

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference68 articles.

1. Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes;Drilon;Nat. Rev. Clin. Oncol.,2018

2. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry;Gautschi;J. Clin. Oncol.,2017

3. Precision Targeted Therapy with BLU-667 for RET-Driven Cancers;Subbiah;Cancer Discov.,2018

4. Advances in Targeting RET-Dependent Cancers;Subbiah;Cancer Discov.,2020

5. The development of potent, selective RET inhibitors that target both wildtype RET and prospectively identified resistance mutations to multikinase inhibitors;Rahal;Cancer Res.,2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiovascular toxicities of selective ret-specific tyrosine kinase inhibitors: a pharmacovigilance study based on the United States Food and Drug Administration Adverse Event Reporting System database;Expert Opinion on Drug Safety;2024-08-19

2. Interstitial lung disease in patients enrolled in early-phase clinical trials: the ILDE study;ESMO Open;2024-08

3. Tissue-Agnostic Cancer Therapy Approvals;Surgical Oncology Clinics of North America;2023-12